These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23688317)

  • 21. Glucose, cholesterol and blood pressure in type II diabetes: A longitudinal observational study comparing patients with and without severe mental illness.
    Smith R; Han L; Ali S; Prady SL; Taylor J; Hughes T; Ajjan RA; Siddiqi N; Doran T
    J Psychiatr Ment Health Nurs; 2019 Nov; 26(9-10):347-357. PubMed ID: 31287193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug prescription rates in secondary cardiovascular prevention in old age: Do vulnerability and severity of the history of cardiovascular disease matter?
    van Peet PG; Gussekloo J; den Elzen WP; Blom JW; de Waal MW; de Ruijter W
    Scand J Prim Health Care; 2015; 33(4):260-8. PubMed ID: 26683286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
    ; Buse JB; Bigger JT; Byington RP; Cooper LS; Cushman WC; Friedewald WT; Genuth S; Gerstein HC; Ginsberg HN; Goff DC; Grimm RH; Margolis KL; Probstfield JL; Simons-Morton DG; Sullivan MD
    Am J Cardiol; 2007 Jun; 99(12A):21i-33i. PubMed ID: 17599422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the relationship between coronary heart disease and type 2 diabetes: a cross-sectional study of secondary prevention among diabetes patients.
    Gjelsvik B; Tran AT; Berg TJ; Bakke Å; Mdala I; Nøkleby K; Cooper JG; Claudi T; Løvaas KF; Thue G; Sandberg S; Jenum AK
    BJGP Open; 2019 Apr; 3(1):bjgpopen18X101636. PubMed ID: 31049416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study.
    Jansen J; Bonner C; McKinn S; Irwig L; Glasziou P; Doust J; Teixeira-Pinto A; Hayen A; Turner R; McCaffery K
    BMJ Open; 2014 May; 4(5):e004812. PubMed ID: 24833688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
    Merton K; Davies MJ; Vijapurkar U; Inman D; Meininger G
    Curr Med Res Opin; 2018 Feb; 34(2):313-318. PubMed ID: 29022746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status.
    Wong ND; Patao C; Wong K; Malik S; Franklin SS; Iloeje U
    Diab Vasc Dis Res; 2013 Nov; 10(6):505-13. PubMed ID: 23975724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening.
    Webb DR; Khunti K; Srinivasan B; Gray LJ; Taub N; Campbell S; Barnett J; Henson J; Hiles S; Farooqi A; Griffin SJ; Wareham NJ; Davies MJ
    Trials; 2010 Feb; 11():16. PubMed ID: 20170482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HbA1c, systolic blood pressure variability and diabetic retinopathy in Asian type 2 diabetics.
    Foo V; Quah J; Cheung G; Tan NC; Ma Zar KL; Chan CM; Lamoureux E; Tien Yin W; Tan G; Sabanayagam C
    J Diabetes; 2017 Feb; 9(2):200-207. PubMed ID: 27043025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark.
    Safai N; Carstensen B; Vestergaard H; Ridderstråle M
    BMJ Open; 2018 Mar; 8(3):e019214. PubMed ID: 29550776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey.
    Vulic D; Lee BT; Dede J; Lopez VA; Wong ND
    Am J Cardiovasc Drugs; 2010; 10(2):109-14. PubMed ID: 20334448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteinuria modifies the effect of systolic blood pressure on total and cardiovascular disease mortality in patients with type 2 diabetes.
    Vepsäläinen T; Laakso M; Kantola I; Lehto S; Juutilainen A; Rönnemaa T
    J Intern Med; 2012 Dec; 272(6):611-9. PubMed ID: 22891848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Barnard S; Perel P; Free C
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012675. PubMed ID: 29932455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study.
    Wong ND; Zhao Y; Patel R; Patao C; Malik S; Bertoni AG; Correa A; Folsom AR; Kachroo S; Mukherjee J; Taylor H; Selvin E
    Diabetes Care; 2016 May; 39(5):668-76. PubMed ID: 27208374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular disease (CVD) limbo: how soon and low should we go to prevent CVD in diabetes?
    Maahs DM
    Diabetes Technol Ther; 2012 Jun; 14(6):449-52. PubMed ID: 22472062
    [No Abstract]   [Full Text] [Related]  

  • 37. Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes.
    Berthold HK; Bestehorn KP; Krone W; Gouni-Berthold I
    Diabet Med; 2010 Mar; 27(3):303-8. PubMed ID: 20536493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Features and Microvascular Complications Risk Factors of Early-onset Type 2 Diabetes Mellitus.
    Huang JX; Liao YF; Li YM
    Curr Med Sci; 2019 Oct; 39(5):754-758. PubMed ID: 31612393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex-specific differences in glycemic control and cardiovascular risk factors in older patients with insulin-treated type 2 diabetes mellitus.
    Göbl CS; Brannath W; Bozkurt L; Handisurya A; Anderwald C; Luger A; Krebs M; Kautzky-Willer A; Bischof MG
    Gend Med; 2010 Dec; 7(6):593-9. PubMed ID: 21195359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depressive symptoms, serious psychological distress, diabetes distress and cardiovascular risk factor control in patients with type 2 diabetes.
    Winchester RJ; Williams JS; Wolfman TE; Egede LE
    J Diabetes Complications; 2016 Mar; 30(2):312-7. PubMed ID: 26657725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.